Skip to main content
OYE Therapeutics

Novel  High  Concentration  I.V. Caffeine Rapid  Reversal  Agent

Address Limitations of Naloxone 

and 

Increase Available Treatment Options

  Key Distinctions vs. Current Treatment

1. Increases duration of action:  Half-Life is 6 hours
2. Novel Mechanism of action:  Respiratory Stimulant
3. Limits treatment Induced Toxicity and Opioid Withdrawal Sickness
4. Does not Eliminate Pain Control in contrast to naloxone
5. Treats sedative toxidrome (Opioids + Alcohol, Barbiturates, Benzo’s)
Image of military personnel in the build

OYE Therapeutics Selected as a Semi-Finalists in Pepperdine Graziadio’s 2024 Most Fundable Companies in the U.S. 

This recognition highlights OYE’s exceptional potential and innovation in the competitive startup landscape.

Out of more than 4,000 early-stage startups from all 50 states, OYE has distinguished itself through its groundbreaking work in countering respiratory depression and reversing sedation. The selection process, conducted by Pepperdine’s Graziadio Business School, is rigorous and comprehensive, evaluating several key variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise.

"We are honored to be recognized as one of the top early-stage startups in the country," said Brett Dines, CEO and Founder of OYE. "This accolade is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to continuing our mission of providing clinicians with tools to save lives, especially in the ongoing struggle with Opioid Overdose."


Image of military personnel in the build

OYE invited to participate in ACTTION Conference February, 2024